07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Altacor, Esperante deal

Life science investment company Esperante acquired ophthalmology company Altacor for an undisclosed amount. Altacor markets eight products in the U.K. and Ireland, including Clinitas sodium hyaluronate to treat dry eye syndrome. Longcross Advisers LLP was...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Proximagen, Upsher-Smith deal

Specialty pharma Upsher-Smith will acquire the 84% of Proximagen it does not already own for 320p per share in cash. The price, which values Proximagen at about £223 million ($345.7 million), is a 16% premium...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Company News

Altacor, Nicox deal

NicOx said its board of directors unanimously decided not to exercise an option to acquire the 88.2% of ophthalmic company Altacor it does not already own. NicOx said the board determined that the full acquisition...
07:00 , Jun 4, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioAlliance Pharma S.A. (Euronext:BIO) gained €0.08 to €3.30 last week after FDA accepted for review an NDA for Sitavig acyclovir Lauriad to treat recurrent orofacial herpes. The PDUFA date is undisclosed. BioAlliance submitted the...
00:16 , Jun 2, 2012 |  BC Extra  |  Company News

NicOx declines option to acquire Altacor

NicOx S.A. (Euronext:COX) said its board of directors unanimously decided not to exercise an option to acquire the 88.2% of ophthalmic company Altacor Ltd. (Cambridge, U.K.) it does not already own. NicOx said the board...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Company News

Altacor, Nicox deal

NicOx will acquire an 11.8% stake in ophthalmic company Altacor for £2 million ($3.2 million) in cash. NicOx also received an exclusive option to acquire the remaining Altacor shares for an additional £9 million ($14.2...
07:00 , Mar 26, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) lost $1.10 to $14 last week after announcing EMA accepted for review an MAA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.31 to $15.72 last...
00:18 , Mar 22, 2012 |  BC Extra  |  Company News

NicOx gains on option to acquire Altacor

NicOx S.A. (Euronext:COX) gained EUR 1.10 (35%) to EUR 4.22 on Wednesday after saying it will acquire an 11.8% stake in ophthalmic company Altacor Ltd. (Cambridge, U.K.) for L2 million ($3.2 million) in cash. NicOx...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Altacor, Proximagen deal

The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933, the lead compound under the program, to treat glaucoma. Altacor will...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Financial News

Altacor financial update

Altacor raised £1.9 million ($3.1 million) in a second tranche of a series C round, bringing the total amount raised in the round to £3.4 million ($5.5 million). The second tranche was led by NVM...